Global Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Neuromyelitis Optica (Devic’s Syndrome) treatment during 2019. Clinical development activities are being undertaken by more than 20 companies including Abide Therapeutics Inc, Acer Therapeutics Inc, Alexion Pharmaceuticals Inc, Anvil Biosciences, Biogen Inc and others.
A Significant contribution to the Neuromyelitis Optica (Devic’s Syndrome) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Neuromyelitis Optica (Devic’s Syndrome) pipeline included 21 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Neuromyelitis Optica (Devic’s Syndrome) condition and increased access to investments is encouraging growth of Neuromyelitis Optica (Devic’s Syndrome) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Neuromyelitis Optica (Devic’s Syndrome) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Neuromyelitis Optica (Devic’s Syndrome) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Neuromyelitis Optica (Devic’s Syndrome) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Neuromyelitis Optica (Devic’s Syndrome). Further, orphan drug status, fast track designation, grants awarded and other special status for Neuromyelitis Optica (Devic’s Syndrome) pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Neuromyelitis Optica (Devic’s Syndrome) pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Neuromyelitis Optica (Devic’s Syndrome) Pipeline candidates-
A Significant contribution to the Neuromyelitis Optica (Devic’s Syndrome) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Neuromyelitis Optica (Devic’s Syndrome) pipeline included 21 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Neuromyelitis Optica (Devic’s Syndrome) condition and increased access to investments is encouraging growth of Neuromyelitis Optica (Devic’s Syndrome) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Neuromyelitis Optica (Devic’s Syndrome) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Neuromyelitis Optica (Devic’s Syndrome) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Neuromyelitis Optica (Devic’s Syndrome) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Neuromyelitis Optica (Devic’s Syndrome). Further, orphan drug status, fast track designation, grants awarded and other special status for Neuromyelitis Optica (Devic’s Syndrome) pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Neuromyelitis Optica (Devic’s Syndrome) pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Neuromyelitis Optica (Devic’s Syndrome) Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Neuromyelitis Optica (Devic’s Syndrome) drugs
- Late phase: Phase 3 and in-approval Neuromyelitis Optica (Devic’s Syndrome) drugs
- Company overview
- Snapshot
- Neuromyelitis Optica (Devic’s Syndrome) therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Neuromyelitis Optica (Devic’s Syndrome)- Disease Overview
2.2 Neuromyelitis Optica (Devic’s Syndrome)- Pipeline Snapshot
2.3 Neuromyelitis Optica (Devic’s Syndrome)- Pipeline Drugs by Phase
2.4 Neuromyelitis Optica (Devic’s Syndrome)- Pipeline Drugs by Company
2.5 Neuromyelitis Optica (Devic’s Syndrome)- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Abide Therapeutics Inc Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.2 Acer Therapeutics Inc Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.3 Alexion Pharmaceuticals Inc Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.4 Anvil Biosciences Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.5 Biogen Inc Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.6 Bionure Farma SL Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.7 Chord Therapeutics Sarl Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.8 Chugai Pharmaceutical Co Ltd Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.9 Clene Nanomedicine Inc Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.10 Endece LLC Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.11 EnhanX Biopharm Inc Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.12 Fundacio Clinic per a la Recerca Biomedica Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.13 HanAll Biopharma Co Ltd Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.14 Imstem Biotechnology Inc Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.15 LFB SA Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.16 Nihon Pharmaceuticals Co Ltd Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.17 Orion BioScience Inc Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.18 Rongchang Pharmaceutical Co Ltd Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.19 Tolerion Inc Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.20 Vicore Pharma AB Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.21 Viela Bio Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Neuromyelitis Optica (Devic’s Syndrome)- Phase 1 Drug Details
4.2 Neuromyelitis Optica (Devic’s Syndrome)- Phase 1 Drug Overview
4.3 Neuromyelitis Optica (Devic’s Syndrome)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Neuromyelitis Optica (Devic’s Syndrome)- Phase 2 Drug Details
5.2 Neuromyelitis Optica (Devic’s Syndrome)- Phase 2 Drug Overview
5.3 Neuromyelitis Optica (Devic’s Syndrome)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Neuromyelitis Optica (Devic’s Syndrome)- Phase 3 Drug Details
6.2 Neuromyelitis Optica (Devic’s Syndrome)- Phase 3 Drug Overview
6.3 Neuromyelitis Optica (Devic’s Syndrome)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Neuromyelitis Optica (Devic’s Syndrome)- Pre-clinical Phase Drug Details
7.2 Neuromyelitis Optica (Devic’s Syndrome)- Pre-clinical Phase Drug Overview
7.3 Neuromyelitis Optica (Devic’s Syndrome)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Neuromyelitis Optica (Devic’s Syndrome)- Disease Overview
2.2 Neuromyelitis Optica (Devic’s Syndrome)- Pipeline Snapshot
2.3 Neuromyelitis Optica (Devic’s Syndrome)- Pipeline Drugs by Phase
2.4 Neuromyelitis Optica (Devic’s Syndrome)- Pipeline Drugs by Company
2.5 Neuromyelitis Optica (Devic’s Syndrome)- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Abide Therapeutics Inc Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.2 Acer Therapeutics Inc Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.3 Alexion Pharmaceuticals Inc Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.4 Anvil Biosciences Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.5 Biogen Inc Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.6 Bionure Farma SL Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.7 Chord Therapeutics Sarl Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.8 Chugai Pharmaceutical Co Ltd Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.9 Clene Nanomedicine Inc Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.10 Endece LLC Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.11 EnhanX Biopharm Inc Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.12 Fundacio Clinic per a la Recerca Biomedica Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.13 HanAll Biopharma Co Ltd Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.14 Imstem Biotechnology Inc Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.15 LFB SA Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.16 Nihon Pharmaceuticals Co Ltd Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.17 Orion BioScience Inc Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.18 Rongchang Pharmaceutical Co Ltd Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.19 Tolerion Inc Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.20 Vicore Pharma AB Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
3.21 Viela Bio Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Neuromyelitis Optica (Devic’s Syndrome)- Phase 1 Drug Details
4.2 Neuromyelitis Optica (Devic’s Syndrome)- Phase 1 Drug Overview
4.3 Neuromyelitis Optica (Devic’s Syndrome)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Neuromyelitis Optica (Devic’s Syndrome)- Phase 2 Drug Details
5.2 Neuromyelitis Optica (Devic’s Syndrome)- Phase 2 Drug Overview
5.3 Neuromyelitis Optica (Devic’s Syndrome)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Neuromyelitis Optica (Devic’s Syndrome)- Phase 3 Drug Details
6.2 Neuromyelitis Optica (Devic’s Syndrome)- Phase 3 Drug Overview
6.3 Neuromyelitis Optica (Devic’s Syndrome)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Neuromyelitis Optica (Devic’s Syndrome)- Pre-clinical Phase Drug Details
7.2 Neuromyelitis Optica (Devic’s Syndrome)- Pre-clinical Phase Drug Overview
7.3 Neuromyelitis Optica (Devic’s Syndrome)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
